Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients
- Registration Number
- NCT02297763
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
The purpose of this study is to evaluate the efficacy of low dose quetiapine for the prophylaxis of delirium in critically ill patients in medical intensive care unit.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 194
Inclusion Criteria
- Greater than or equal to 19 years of age, admitting to medical ICU, anticipated to stay more than 72hours
Exclusion Criteria
- Female patients who are pregnant or breastfeeding
- active delirium
- Received other anti-psychotic drug before attend the study
- severe bradycardia
- alcohol intoxication
- No written consent from the legal representatives
- Being ill with renal or hepatic failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo placebo The placebo is made of 100mg of corn starch which is melted in 10cc water. quetiapine quetiapine quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
- Primary Outcome Measures
Name Time Method Development of delirium within 14 days after admitting to ICU (Rate) 14 days after admitting to intensive care unit
- Secondary Outcome Measures
Name Time Method Duration of delirium occurring within 14 days after admitting to ICU (Days) 14 days after admitting to ICU Length of stay in ICU and hospital (Days) up to 24 weeks 60 days in hospital mortality (Rate) 60 days after admitting to ICU Duration of mechanical ventilation in ICU (Days) 14days after admitting to intensive care unit